New Report Highlights Toll of Lung Cancer in Maine, Need for Biomarker Testing Coverage

Today, the American Lung Association in Maine released the 2025 “State of Lung Cancer” report, which reveals that more needs to be done to end the burden of this devastating disease on families throughout the state. Lung cancer is the leading cause of cancer deaths here in Maine and across the U.S. The report finds that Maine surpasses U.S. average for screening of high-risk individuals, early diagnosis and treatment, but lung cancer incident rate remains high despite progress, highlighting an urgent need for continued prevention and early detection methods. The report also finds that Maine needs to implement policies to increase biomarker testing for people with lung cancer.

The Lung Association’s eighth annual “State of Lung Cancer” report highlights how the toll of lung cancer varies by state and examines key indicators throughout the U.S., including new cases, survival, early diagnosis, surgical treatment, lack of treatment, screening rates and insurance coverage of comprehensive biomarker testing.

The report found that Maine ranks:

• 44 out of 51 in the nation for rate of new lung cancer cases, at 66.73 per 100,000 (marking a 16% improvement over the past five years but still ranking below average and among the worst. The national rate is 52.8 per 100,000. Lung Cancer Incidence Remains High Despite Progress The state ranks 44th out of 51 nationwide for new lung cancer diagnoses, with a rate of 66.73 cases per 100,000 people—significantly higher than the national average of 52.8. While this reflects a 16% improvement over the past five years, the state still falls among the worst in the country, highlighting an urgent need for continued prevention and early detection efforts.
• 20 out of 39 in the nation for survival, at 29.9%, marking a 28% improvement over past five years. The national rate of people alive five years after a lung cancer diagnosis is 29.7%.
• 16 out of 50 in the nation for early diagnosis, at 29.8% (marking an 18% improvement over past five years). Nationally, only 28.1% of cases are diagnosed at an early stage when the survival rate is much higher.
• 5 out of 51 in the nation for lung cancer screening, at 24.3%. Lung cancer screening with annual low-dose CT scans for people at high risk can reduce the lung cancer death rate by up to 20%. Nationally, only 18.2% of people at high risk were screened.
• 9 out of 49 in the nation for surgery as first course of treatment, at 23.2%. Lung cancer can often be treated with surgery if it is diagnosed at an early stage and has not spread. Nationally, 20.7% of cases underwent surgery.
• 9 out of 49 in the nation for lack of treatment, at 17.2%. Nationally, 21% of cases receive no treatment.
• 35 out of 51 in the nation for smoking, at 14%. Nationally, 11.4% of adults are current smokers. 
• 37 out of 51 in the nation for its radon test results, placing the state in the below average tier compared to other states, with a relatively high percentage of results (36.5%) equal to or worse than the EPA recommended action level.

“In the last decade, we have seen incredible progress, including increases in lung cancer survival and early detection rates. This means that more people in Maine are living longer after a lung cancer diagnosis,” said Lance Boucher, assistant vice president of state public policy for the American Lung Association. “While this progress gives us hope, early detection and survival rates are far too low in our state. Working to increase awareness and access to lung cancer screening and biomarker testing are critical to saving lives. This is why the state must step in to ensure their residents have access to the best lung cancer care.”

The “State of Lung Cancer” report also examines insurance coverage of comprehensive biomarker testing across the U.S. Lung cancer biomarker testing, sometimes referred to as tumor, molecular, genomic or genetic testing, looks for changes in the tumor's DNA. The results of the test may show biomarkers that can help determine what treatment options would be best for an individual patient. Insurance coverage of biomarker testing is important for removing a cost barrier to people with lung cancer, but coverage for biomarker testing is only required in some states. The report found that Maine does not require insurance coverage of comprehensive biomarker testing.

The 2025 “State of Lung Cancer” report highlights opportunities for states to reduce the burden of lung cancer and encourages everyone to help end lung cancer. This year, the American Lung Association calls for the state to implement policies to require insurance coverage of comprehensive biomarker testing. Learn more about the report and take action at Lung.org/solc.

Get involved and help the mission of the American Lung Association. The Trek Across Maine is coming up June 19-21. Learn more at TrekAcrossMaine.org.